Denosumab-BMWO NDC 72606-059

NDC codes

FDA NDC Directory

Product NDC (as listed)72606-059Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72606-0059Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72606-059-01	72606005901	1 VIAL, SINGLE-USE in 1 CARTON (72606-059-01) / 1.7 mL in 1 VIAL, SINGLE-USEMarketed from Sep 10, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Denosumab-BMWO
Generic name (nonproprietary): denosumab-bmwo
Active ingredients: Denosumab — 120 mg/1.7mL
Dosage form: Injection
Route: Subcutaneous
Labeler: CELLTRION USA, Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761404
Marketing start: Sep 10, 2025
Listing expires: Dec 31, 2027
Other FDA classes: RANK Ligand Blocking Activity (Mechanism)
Identifiers: Product ID 72606-059_515e94c3-ab8d-4c35-8e7c-7083fd423d60SPL ID 515e94c3-ab8d-4c35-8e7c-7083fd423d60SPL set ID d378622d-3a13-4918-ae18-3375cd10d270RxCUI 2717866UNII 4EQZ6YO2HIUPC 0372606059011
Pharmacologic class: RANK Ligand Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0897 — Injection, denosumab, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

Denosumab biosimilars have their own HCPCS codes.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472606005901 followed by a unit qualifier and the quantity

Package 72606-0059-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 5, 2026.

Indications (excerpt from the label)

Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Denosumab-bmwo is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761404

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761404
Product	Strength	Form · route	Labeler	Product NDC
Stoboclodenosumab-bmwo	Denosumab 60 mg/mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-037
Osenveltdenosumab-bmwo	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-038
Denosumab-BMWO	Denosumab 60 mg/mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-058